Pharma BD Deal Intelligence
AbbVie's $5.8B bet on Stemcentrx delivered rovalpituzumab tesirine, an anti-DLL3 antibody-drug conjugate for small cell lung cancer that ultimately failed in Phase 3 and was discontinued—one of oncology's costliest clinical washouts, reflected in depressed critic and outcome scores.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.
AbbVie acquired Stemcentrx for its novel late-stage Rova-T compound showing 44% response rates in DLL3-expressing small cell lung cancer — an area of enormous…
Rova-T: the story of AbbVie's multi-billion dollar failure. Even without hindsight, buying Stemcentrx outright for $5.8B based on Phase 1 data looked bold at…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.
DLL3+ solid tumors: Rova-T (rovalpituzumab tesirine, AbbVie/Stemcentrx lead asset) discontinued after Phase 3 failures in SCLC (TAHOE, MERU trials 2018-2019). The DLL3 target was ultimately validated in a different format: Amgen's tarlatamab (Imdelltra, DLL3×CD3 BiTE, FDA-approved May 2024 for small cell lung cancer 2L+). Other DLL3-directed programs in development include Boehringer Ingelheim (BI 764532), Harpoon's HPN328 (licensed to Merck as MK-6070), and Phanes Therapeutics. Stemcentrx's other DLL3 assets (SC-002, SC-003) discontinued. AbbVie's $5.8B Stemcentrx bet was written down substantially after Rova-T failures.
AbbVie/Stemcentrx was a platform acquisition focused on Rova-T (DLL3 ADC; discontinued post-Phase-3 failure) and the broader tumor-initiating-cell platform. Competitive landscape applies per sub-asset: see the Solid Tumors (DLL3+) row for DLL3 competitor framing (Amgen tarlatamab/Imdelltra, Imdelltra competitors).
Small cell lung cancer (SCLC) is a historically stagnant ~$3B market recently reshaped by immunotherapy and DLL3-targeted agents. Platinum-etoposide chemotherapy remains the chemo backbone in both extensive-stage (ES-SCLC) and limited-stage (LS-SCLC) disease. Anti-PD-L1 + chemo (1L ES-SCLC standard): atezolizumab (Tecentriq, Roche; IMpower133, approved March 2019) and durvalumab (Imfinzi, AstraZeneca; CASPIAN, approved March 2020). Anti-PD-1 consolidation: durvalumab (Imfinzi, AstraZeneca; ADRIATIC LS-SCLC consolidation, FDA-approved December 2024) and pembrolizumab (Keytruda, Merck; post-platinum 3L). DLL3-targeted therapies (direct class to Rova-T): tarlatamab (Imdelltra, Amgen; DLL3xCD3 bispecific T-cell engager) received FDA accelerated approval May 2024 for 2L+ ES-SCLC based on DeLLphi-301, representing the successful MOA Rova-T failed to achieve. Chemotherapy (2L+): lurbinectedin (Zepzelca, Jazz Pharmaceuticals; approved 2020, ~$300M 2023) and topotecan (generic). PARP inhibitors: olaparib (Lynparza, AZ/Merck) studied but not approved in SCLC. Rova-T was discontinued 2019 after TAHOE and MERU Phase 3 failures, vacating the DLL3 ADC space; Amgen's tarlatamab ultimately validated DLL3 as a target with a superior MOA format (bispecific vs. ADC).
AbbVie Inc. completed its acquisition of Stemcentrx Inc. for $9.8B. AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.
Far below expectations despite DLL3-high patient selection. Part of AbbVie Inc.'s $9.8B deal to acquire Stemcentrx Inc..
Patients on Rova-T died sooner than chemo arm, devastating safety signal. Part of AbbVie Inc.'s $9.8B deal to acquire Stemcentrx Inc..
Wrote off most of $5.8B upfront after multiple trial failures. Reflects financial performance following AbbVie Inc.'s $9.8B acquisition of Stemcentrx Inc..
MERU Phase 3 also failed. Program terminated. Total loss ~$5.8B. Part of AbbVie Inc.'s $9.8B deal to acquire Stemcentrx Inc..
One of pharma costliest failures. 16% ORR, excess deaths, $4B writedown. No product.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Stemcentrx Inc. (this deal) | 2012 | $5.8B | 16 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2012 deals · AbbVie Inc. deals · Oncology deals